Browse the evidence

Differences between the groups regarding the primary outcome (composite score of physical functioning) could not be identified due to early termination.

Early termination of studies can limit the ability to draw conclusions about treatment effects.

The use of GLP-1RA medications has been associated with increased hypoglycaemia risk in patients treated with concomitant antihyperglycaemic medications.

Clinicians should monitor for hypoglycaemia when initiating GLP-1RA therapy in patients on other antihyperglycaemic medications.

GIP(1-30)NH2 and GIP(1-42) have similar effects on human pancreatic islets.

Both GIP variants can be expected to have similar effects on insulin and glucagon secretion in pancreatic islets.

There were no significant between-group differences in VAT volume after 6 months or 12 months.

Dietary interventions may not differ significantly in their effects on VAT volume over time.

The SDOC definition has high discriminatory accuracy for identifying ADL disability.

The SDOC criteria can be effectively used to assess risk of ADL disability in older adults.

Demographics associated with higher prescription period prevalence included non-Hispanic Black race and ethnicity, female sex, and older age.

Understanding these demographic factors can help tailor interventions and support for specific groups.

Semaglutide is available in two formulations: once-weekly subcutaneous and once-daily oral.

Practitioners can offer patients a choice between two formulations of semaglutide for weight management.

Further study is needed to understand GIP's implications on weight reduction and other diseases.

Practitioners should be aware of the potential broader implications of GIP therapies.

Only 8% of eligible candidates with type 2 diabetes are prescribed GLP-1RA.

Cardiologists should be aware of the low prescription rates of GLP-1RA among eligible patients.

The uptake of GLP-1RA in clinical practice is low among cardiologists.

Efforts are needed to increase awareness and education among cardiologists regarding GLP-1RA.

The supramolecular GLP-1 receptor agonist (PA-GLP1) formulation achieved sustained serum concentrations for at least 40 days in a rat model of type 2 diabetes.

This formulation may provide a long-lasting treatment option for diabetes management.

The number of incident GLP-1 RA users in France increased from 5117 in January 2017 to 15,193 in June 2023.

Healthcare providers should be aware of the significant increase in GLP-1 RA prescriptions.

If 1%, 5%, or 10% of the population aged 60 years or older is treated with semaglutide, the annual Medicare costs will translate to excess of $2.6 billion, $13.3 billion, and $26.8 billion, respectively.

Understanding these cost projections is crucial for policymakers and healthcare planners.

Concerns regarding operative risks, irreversibility, and excess costs limit the broader clinical use of metabolic and bariatric surgeries.

Practitioners should be aware of these concerns when discussing surgical options with patients.

Continuation of GLP-1RAs did not appear to be associated with an increased incidence of residual gastric contents during EGD.

Practitioners can consider continuing GLP-1RAs during EGD without increased risk of residual gastric contents.

Rates of early termination of EGD were similar between groups.

Practitioners can expect similar rates of early termination of EGD regardless of GLP-1RA continuation.

There were no aspiration events in either group.

Practitioners can be reassured that there is no increased risk of aspiration events with GLP-1RA use during EGD.

The findings support nephroprotective mechanisms of GLP-1RAs independent of body weight and glycemic control.

This indicates that GLP-1RAs may be beneficial for kidney health beyond their metabolic effects.

Body mass index (BMI) requirements for gender-affirming surgeries (GAS) present an obstacle to gender transition for many transgender and gender diverse (TGD) people.

Clinicians should be aware of the BMI-related barriers faced by TGD patients when considering GAS.

There is limited evidence supporting the effectiveness of n-3-PUFA supplementation in improving or preventing loss of lean mass in both younger and older healthy adults, as well as clinical populations including oncologic patients.

Practitioners should be cautious in recommending n-3-PUFA supplementation for lean mass improvement.

Most systematic reviews concluded that n-3-PUFA supplementation did not significantly affect strength.

Strength training recommendations should not rely on n-3-PUFA supplementation.

There was no consistent impact of n-3-PUFA supplementation on functional outcome measures.

Functional improvements should not be expected from n-3-PUFA supplementation.

No statistically significant associations were identified for SGLT2 inhibitors regarding hematologic malignancy risk.

SGLT2 inhibitors may not pose a risk for hematologic malignancies, making them a safer choice in this regard.

BGM1812 was developed through a step-by-step modification process guided by structure-based drug design and molecular dynamics simulations.

Understanding the development process can inform future drug design strategies.